WORLD ORPHAN DRUG SUMMIT 2011

Recent blockbuster success has accelerated interest and investment in the orphan drug market and many companies are now keen to capitalise on this potential. However, commercial realisation of orphan drugs is not straight forward, and significant challenges exist within the development process and in the market.
The World Orphan Drug Summit brings together the thought leaders from pharma and biotechs to challenges in tackle route to market, pricing and reimbursement, and development of rare disease treatments. It’s focus is on addressing challenges facing orphan drug stakeholders in depth and provide real, practical solutions to companies operating in the space.

This meeting has been put together with support from many of the main players in the orphan drug field, including GlaxoSmithKline, Genzyme and Sanofi-Aventis. The World Orphan Drug Summit will tackle challenges that are currently slowing development, market authorisation and patient access to treatment. We will focus on delivering in depth discussion and practical solutions to provide you with the strategies to grow your orphan drug business.